OwenAO'ConnorMD

Oncology • New York, NY

Cutaneous Lymphoma, Hematologic Oncology

The Center for Lymphoid Malignancies at Columbia University Medical Center

Join to view full profile

Dr. O'Connor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. O'Connor's full profile

Already have an account?

Office
51 West 51st Street
Suite 200
New York, NY 10019
Phone+1 212-326-5720

Fax+1 212-326-5725
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 2000
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

Certifications & Licensure

NY State Medical License 1996 - 2026
VA State Medical License 2021 - 2024

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2012-2014
Top Doctors: New York Metro Area Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Join now to see all

Clinical Trials

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Start of enrollment: 2002 Aug 01
Completed
Phase 1, Phase 2
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders Start of enrollment: 2002 Oct 01
Completed
Phase 2
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Start of enrollment: 2008 Jun 01
Completed
Phase 1
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) Start of enrollment: 2012 Jul 01
Completed
Phase 1, Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2013 Nov 01
Terminated
Phase 1, Phase 2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Start of enrollment: 2016 Mar 01
Completed
Phase 1
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Start of enrollment: 2016 May 25
Terminated
Phase 2, Phase 3
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Start of enrollment: 2018 May 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

11 citations
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enric...> ;Blood Advances. 2021 Sep 21
1 citations
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
Kana Oiwa, Naoko Hosono, Rie Nishi, Luigi Scotto, Owen A. O'Connor, Takahiro Yamauchi> ;BMC Cancer. 2021 Jul 31
3 citations
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
Luigi Scotto, Cristina Kinahan, Eugene Douglass, Changchun Deng, Maryam Safari, Beatrice Casadei, Enrica Marchi, Jennifer K. Lue, Francesca Montanari, Lorenzo Falchi, ...> ;Molecular Cancer Therapeutics. 2021 Jun 9
11 citations
R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
Maryam Safari, Thomas Litman, Robert W. Robey, Andrés Aguilera, Arup R. Chakraborty, William C. Reinhold, Agnes Basseville, Lubov Petrukhin, Luigi Scotto, Owen A. O'Co...> ;Molecular Cancer Research. 2021 May 28
15 citations
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/...
Wei Zhang, Liping Su, Lihong Liu, Yuhuan Gao, Quan-Shun Wang, Hang Su, Yuhuan Song, Huilai Zhang, Jing Shen, Hongmei Jing, Shuye Wang, Xi-Nan Cen, Hui Liu, Aichun Liu,...> ;Cancer Biology & Medicine. 2021 Mar 22
3 citations
Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL).
Helen Ma, Owen A. O'Connor, Enrica Marchi> ;Seminars in Hematology. 2021 Mar 19
82 citations
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny, Chan Yoon Cheah, Tycel Phillips, Ewa L...> ;Journal of Clinical Oncology. 2021 Mar 8
93 citations
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary Elizabeth Percival, Anjali S. ...> ;Clinical Cancer Research. 2021 Apr 15
N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κB.
Matko Kalac, Michael Mangone, Alison Rinderspacher, Shi-Xian Deng, Luigi Scotto, Michael Markson, Mukesh Bansal, Andrea Califano, Donald W. Landry, Owen A. O'Connor> ;Iscience. 2020 Nov 30
93 citations
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid, Owen A. O'Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T...> ;Blood. 2021 May 13
75 citations
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K. Lue, Francesca Montanari, Enrica Marchi, Changchun Deng, Hye A. Kim, Aishling M. Rada, Alice T. Jacob, Cristina Kin...> ;Blood. 2020 Nov 10
9 citations
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.
Jennifer K. Lue, Owen A. O'Connor> ;The Lancet. Haematology. 2020 Nov 1
14 citations
The peripheral T-cell lymphomas: an unusual path to cure.
Helen Ma, Enrica Marchi, Owen A. O'Connor> ;The Lancet. Haematology. 2020 Oct 1
10 citations
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
Jennifer K. Lue, Owen A. O'Connor, Francesco Bertoni> ;Annals of Lymphoma. 2020 Sep 30
4 citations
ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest.
Luigi Scotto, Xavier O. Jirau Serrano, Kelly Zullo, Cristina Kinahan, Changchun Deng, Ahmed Sawas, Susan E. Bates, Owen A. O'Connor> ;Oncotarget. 2020 Sep 15
Cancer testis antigen expression across T-cell lymphoma subtypes
Helen Ma, Craig R. Soderquist, Enrica Marchi, Luigi Scotto, Govind Bhagat, Owen A. O'Connor> ;Hematological Oncology. 2020 Aug 14
1 citations
Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers.
Luigi Scotto, Cristina Kinahan, Beatrice Casadei, Michael Mangone, Eugene Douglass, Vundavalli V. Murty, Enrica Marchi, Helen Ma, Changchun George, Francesca Montanari...> ;Genes, Chromosomes & Cancer. 2020 Jul 30
1 citations
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or r...
Ahmed Sawas, Helen Ma, John Kuruvilla, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Francesca Montanari, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Jos...> ;Leukemia & Lymphoma. 2020 Jul 28
5 citations
The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.
Cristina Kinahan, Michael Mangone, Luigi Scotto, Michele Visentin, Enrica Marchi, Hearn Jay Cho, Owen A. O'Connor> ;Oncotarget. 2020 May 5
4 citations
Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Ahmed Sawas, Helen Ma, Andrei R. Shustov, Pamela Hsu, Gajanan Bhat, Mark Acosta, Steven M. Horwitz, Owen A. O'Connor> ;Leukemia & Lymphoma. 2020 Apr 26
21 citations
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Beh...> ;British Journal of Haematology. 2020 Feb 12
15 citations
Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials.
Helen Ma, Bin Cheng, Lorenzo Falchi, Enrica Marchi, Ahmed Sawas, Govind Bhagat, Owen A. O'Connor> ;Hematological Oncology. 2020 Feb 1
39 citations
The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management.
Enrica Marchi, Owen A. O'Connor> ;CA. 2020 Jan 1
59 citations
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar...> ;Clinical Cancer Research. 2019 Dec 1
Nurturing a diet rich in PTCL.
Owen A. O'Connor> ;Blood. 2019 Oct 24
Join now to see all

Abstracts/Posters

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas
Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes
Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operatio...
2019 ASCO Annual Meeting - 6/1/2019
Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Owen a. O'Connor, M.D., Ph.D., Is Recognized by Continental Who's WhoSeptember 21st, 2022
Acalabrutinib MCL Approval Raises Sequencing QuestionsNovember 15th, 2017
FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent'November 18th, 2023